As mentioned above, Pep19 is an exciting novel CB1R-targeting molecule to treat overweight, obesity, and metabolic disorders because it does not induce anxiety or depression-like symptoms, nor can it induce cannabinoid tetrad behavior or activate cerebral areas related to CB1R activation [67]. This evidence concerns the gene CNR1 and obesity disorder.